PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15986708

Study of copper sulfide crystallization in PEO-SDS solutions.

Maria Orphanou·Epameinondas Leontidis·Tasoula Kyprianidou-Leodidou·Petros Koutsoukos·Kyriacos C Kyriacou
View original source ↗Export metadata ↓

Abstract

The crystallization of copper sulfide in aqueous supersaturated solutions in the presence of the polymer poly(ethylene oxide), PEO, and the surfactant sodium dodecyl sulfate, SDS, was investigated. In these systems, copper sulfide precipitation competes with the reaction between copper cations and dodecyl sulfate anions. The competition of the two reactions may affect the reaction products significantly; therefore it is important to study the properties of the surfactant salt, copper dodecyl sulfate (Cu(DS)2), in detail. The thermodynamic solubility constant of Cu(DS)2 was measured at 8 degrees C and was equal to (2.4 +/- 0.4) x 10(-10) M3. The Krafft point of Cu(DS)2 and its solubility curve (precipitation temperature for a range of concentrations) were also measured. The latter was found to be very close to room temperature. Temperature is thus a very significant parameter in these systems and must be carefully controlled in all experiments. The crystallization of copper sulfide in PEO-SDS solutions was investigated in solutions with compositions above and below the solubility curve. Copper sulfide nanoparticles predominate and are stabilized at temperatures above the solubility curve. Surprisingly, at temperatures below the solubility curve CuxS coexists with Cu(DS)2, which appears in the form of lamellar crystals. The system is further complicated by the presence of at least two different types of copper sulfides corresponding to different oxidation states of copper. Our results suggest that the predominance of Cu(DS)2 at lower temperatures is due to its limited solubility and is modified by the CuI/CuII redox equilibrium in combination with the solution pH.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Maria Orphanou, Epameinondas Leontidis, Tasoula Kyprianidou-Leodidou, Petros Koutsoukos, Kyriacos C Kyriacou. 2004-06-22. Study of copper sulfide crystallization in PEO-SDS solutions.. https://doi.org/10.1021/la036372d

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗